MEDIFLY
Commercial- Indications
- Chronic wounds
Company intelligence / Profile preview
Cuprina Holdings
Singapore, Singaporemedifly.it ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Clinical data from Singapore shows a limb salvage rate of up to 90.9% and wound closure rate of ~45% among high-risk patients using MEDIFLY maggot debridement therapy.
- Therapeutic areas
- DermatologyCardiovascularEndocrinology
- Modalities
- Live biotherapeutic product therapyDeviceBiologic
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Notable partnerships with local hospitals and regional distributors; seeking global partners for expansion
Beyond the preview
Go deeper on Cuprina Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cuprina Holdings.